The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced MSS rectal cancer.
Trial Details
- NCT ID
- NCT06254521
- Phase
- PHASE2
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Status
- RECRUITING
- Cancer Type
- Colorectal Cancer
- Interventions
- Tislelizumab combined with chemotherapy
- Locations (sample)
- Nanning, Guangxi, China|22.81667,108.31667
Key Eligibility Criteria
- Age ≥18 years old and ≤70 years old.
- Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemi…
- The lower edge of the tumor is less than 12cm from the anus as measured by colonoscopy and MRI,or TRUS.
- It was confirmed by magnetic resonance imaging (MRI) or intracavitary ultrasound of the rectum as T3-4 or N+, and M0 by enhanced CT.
For full eligibility, visit ClinicalTrials.gov.